stoxline Quote Chart Rank Option Currency Glossary
  
60 Degrees Pharmaceuticals, Inc. (SXTP)
0.2424  -0.004 (-1.43%)    07-12 14:57
Open: 0.2489
High: 0.2489
Volume: 125,039
  
Pre. Close: 0.246
Low: 0.2361
Market Cap: 3(M)
Technical analysis
2024-07-12 2:55:10 PM
Short term     
Mid term     
Targets 6-month :  0.38 1-year :  0.46
Resists First :  0.32 Second :  0.39
Pivot price 0.25
Supports First :  0.21 Second :  0.17
MAs MA(5) :  0.23 MA(20) :  0.25
MA(100) :  0.26 MA(250) :  0.71
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  36.1 D(3) :  29.9
RSI RSI(14): 45.6
52-week High :  3.79 Low :  0.2
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ SXTP ] has closed above bottom band by 44.6%. Bollinger Bands are 10.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.27 - 0.27 0.27 - 0.27
Low: 0.22 - 0.22 0.22 - 0.22
Close: 0.24 - 0.25 0.25 - 0.25
Company Description

60 Degrees Pharmaceuticals, Inc. operates as a specialty pharmaceutical company that engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19; Tafenoquine for fungal lung infections, tick-borne diseases, candidiasis, and other infectious and non-infectious diseases; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is based in Washington, District of Columbia.

Headline News

Tue, 09 Jul 2024
60 Degrees Pharma Announces IRB Approval of Clinical Study - GlobeNewswire

Mon, 01 Jul 2024
60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) Sees Significant Growth in Short Interest - Defense World

Thu, 27 Jun 2024
First Patient Enrolled in 60 Degrees Pharmaceuticals - GlobeNewswire

Wed, 26 Jun 2024
60 Degrees Pharmaceuticals (SXTP) vs. The Competition Head-To-Head Survey - Defense World

Tue, 11 Jun 2024
60 Degrees Pharmaceuticals Receives FDA Orphan Drug - GlobeNewswire

Thu, 30 May 2024
Enrollment in 60 Degrees Pharmaceuticals Clinical Trial of - GlobeNewswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Neutral
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Outperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 12 (M)
Shares Float 9 (M)
Held by Insiders 23.6 (%)
Held by Institutions 4 (%)
Shares Short 323 (K)
Shares Short P.Month 89 (K)
Stock Financials
EPS -0.06
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -0.24
Profit Margin -194.4 %
Operating Margin -911.6 %
Return on Assets (ttm) -43.4 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth 580.5 %
Gross Profit (p.s.) 0
Sales Per Share 0.03
EBITDA (p.s.) -0.45
Qtrly Earnings Growth 0 %
Operating Cash Flow -5 (M)
Levered Free Cash Flow -3 (M)
Stock Valuations
PE Ratio -4.14
PEG Ratio 0
Price to Book value -1.08
Price to Sales 8
Price to Cash Flow -0.58
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android